Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Given Consensus Recommendation of "Hold" by Analysts

Key Points

• Kestra Medical Technologies has a consensus “Hold” rating from seven analysts, with four buys, two holds and one sell. The average 12-month price target is $28.14, close to the stock’s reported $28 price.
• KMTS reported a quarterly loss of $0.67 per share, missing the $0.59 consensus estimate, on $28.64 million in revenue; analysts expect a full-year loss of $2.29 per share.
• Insiders sold 238,164 shares worth approximately $5.6 million over the past 90 days, primarily to cover tax obligations tied to vested equity awards.

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) has been assigned an average rating of "Hold" from the seven ratings firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $28.1429.

Several equities analysts recently issued reports on KMTS shares. Wolfe Research set a $30.00 price objective on Kestra Medical Technologies in a research report on Wednesday, July 15th. JPMorgan Chase & Co. assumed coverage on Kestra Medical Technologies in a report on Monday. They issued an "overweight" rating and a $30.00 target price for the company. Weiss Ratings upgraded Kestra Medical Technologies from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday. Oppenheimer assumed coverage on Kestra Medical Technologies in a report on Tuesday, July 21st. They set a "market perform" rating on the stock. Finally, BTIG Research increased their price objective on Kestra Medical Technologies from $30.00 to $32.00 and gave the company a "buy" rating in a research report on Wednesday, July 15th.

Insider Activity

In other news, insider Brian Daniel Webster sold 51,900 shares of Kestra Medical Technologies stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $24.52, for a total value of $1,272,588.00. Following the completion of the sale, the insider directly owned 475,215 shares in the company, valued at $11,652,271.80. The trade was a 9.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Timothy P. Moran sold 2,380 shares of the business's stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $23.76, for a total transaction of $56,548.80. Following the transaction, the insider directly owned 66,345 shares of the company's stock, valued at $1,576,357.20. The trade was a 3.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 238,164 shares of company stock worth $5,603,152. 5.30% of the stock is owned by corporate insiders.

Institutional Trading of Kestra Medical Technologies

A number of hedge funds have recently bought and sold shares of KMTS. Russell Investments Group Ltd. grew its stake in shares of Kestra Medical Technologies by 43.5% during the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company's stock valued at $41,000 after purchasing an additional 474 shares during the period. Brown Brothers Harriman & Co. grew its position in Kestra Medical Technologies by 26.8% during the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company's stock valued at $74,000 after buying an additional 656 shares during the period. Rhumbline Advisers increased its holdings in Kestra Medical Technologies by 7.3% during the third quarter. Rhumbline Advisers now owns 12,925 shares of the company's stock valued at $307,000 after buying an additional 874 shares during the last quarter. Farther Finance Advisors LLC bought a new position in Kestra Medical Technologies in the fourth quarter worth approximately $31,000. Finally, Police & Firemen s Retirement System of New Jersey boosted its stake in shares of Kestra Medical Technologies by 34.6% during the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 5,420 shares of the company's stock worth $144,000 after acquiring an additional 1,392 shares during the last quarter.

Kestra Medical Technologies Stock Up 0.4%

NASDAQ:KMTS opened at $28.00 on Thursday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.41 and a current ratio of 4.41. The firm has a market cap of $1.64 billion, a P/E ratio of -11.57 and a beta of 0.58. Kestra Medical Technologies has a fifty-two week low of $15.06 and a fifty-two week high of $30.00. The firm has a 50-day simple moving average of $23.49 and a two-hundred day simple moving average of $22.66.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last issued its earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The firm had revenue of $28.64 million during the quarter. Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%. Analysts predict that Kestra Medical Technologies will post -2.29 earnings per share for the current fiscal year.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source